Respiratory syncytial virus: current progress in vaccine development.

Respiratory syncytial virus (RSV) is the etiological agent for a serious lower respiratory tract disease responsible for close to 200,000 annual deaths worldwide. The first infection is generally most severe, while re-infections usually associate with a milder disease. This observation and the finding that re-infection risks are inversely associated with neutralizing antibody titers suggest that immune responses generated toward a first RSV exposure can significantly reduce morbidity and mortality throughout life. For more than half a century, researchers have endeavored to design a vaccine for RSV that can mimic or improve upon natural protective immunity without adverse events. The virus is herein described together with the hurdles that must be overcome to develop a vaccine and some current vaccine development approaches.

Citation

Rajeev Rudraraju, Bart G Jones, Robert Sealy, Sherri L Surman, Julia L Hurwitz. Respiratory syncytial virus: current progress in vaccine development. Viruses. 2013 Feb 05;5(2):577-94

Mesh Tags

Substances

PMID: 23385470

search → result